ReviewCurrent drug targets2026
Long Non-coding RNAs in Non-small Cell Lung Carcinoma: Regulatory Mechanisms, Diagnostic Potential, and Therapeutic Perspectives.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong noncoding RNAs (lncRNAs) are a unique class of RNA molecules that do not code for proteins but play a significant role in regulating various cellular processes. This article aims to contribute to a better understanding of lncRNA biology in NSCLC and to inspire further research that will improve the diagnosis, treatment, and prevention of this deadly disease.
methodsA literature review was performed using PubMed, Scopus, and Web of Science to analyze studies on lncRNAs in NSCLC published between 2015 and 2025.
resultsIn NSCLC, lncRNAs are commonly dysregulated and can function as either oncogenic or tumor-suppressive regulators, contributing to cancer development and progression. They regulate gene expression directly, act as competitive endogenous RNAs that bind to microRNAs and proteins, and interact with RNA-binding proteins. Furthermore, lncRNAs influence the tumor immune microenvironment, alter cellular metabolism, maintain cancer stem cell properties, and induce angiogenesis by activating specific signaling pathways. LncRNAs have attracted increasing attention for their roles as diagnostic and prognostic biomarkers in liquid biopsies and for their therapeutic relevance in NSCLC. DISCUSSION: This review examines the critical roles and diverse functions of lncRNAs, emphasizing their clinical applicability, recent advances in research, existing challenges, novel approaches, and prospects for NSCLC treatment.
conclusionBy synthesizing recent findings, this study highlights the significant role of lncRNAs in carcinogenesis, encourages further research in this field, and uncovers the complex network of lncRNA-mediated regulatory effects that could lead to innovative diagnostic tools and therapeutic interventions.
Indexed as
Identifiers
41582572What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.